Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion

被引:33
作者
Wade, M
Baker, FJ
Roscigno, R
DellaMaestra, W
Arneson, CP
Hunt, TL
Lai, AA
机构
[1] United Therapeut Corp, Res Triangle Pk, NC 27709 USA
[2] CPKD Solut LLC, Res Triangle Pk, NC USA
[3] PPD Dev, Austin, TX USA
关键词
treprostinil sodium; Remodulin((R)); subcutaneous infusion; chronic pharmacokinetics; pulmonary; arterial hypertension; prostacyclin;
D O I
10.1177/0091270004264638
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this study was to assess the pharmacokinetics and safety of treprostinil sodium administered as a 28-day continuous subcutaneous infusion at escalating infusion rates of 2.5 to 15 ng/kg/min in normal subjects. Fourteen healthy adult volunteers received a 28-day continuous subcutaneous infusion of treprostinil at escalating infusion rates of 2.5, 5, 10, and 15 ng/kg/min. Doses were escalated every 7 days with no washouts between escalations. Serial plasma samples were collected predosing, during dosing, and postdosing. Samples were also collected every 3 hours on Day 7 of each dosing period to evalutate diurnal variation over 24 hour steady-state interval. Plasma treprostinil concentration was measured by a validated liquid chromatography atmospheric pressure ionization tandem mass spectrometry (LC/MS/MS) method with a lower limit of quantitation (LLOQ) of 25 pg/mL. Distinct steady states were achieved for each of the four treprostinil concentration versus targeted dose yielded a fitted line with an r(2) of 0.92. Variation in apparent plasma clearance for the four doses was small (i.e., 9.77-10.4 mL/kg/min). Consistent diurnal cycles of two peak and two trough treprostinil concentrations were observed over a 24-hour steady-state interval for each dose with peak levels 20% to 30% higher that trough levels. The terminal half-life of treprostinil was 2.93 hours. Intersubject variability for mean pharmacokinetic parameters was small (coefficients of variation ranging from 13.6%-25.5%). At clinically relevant does, the pharmacokinetics of treprostinil were linear and dose independent with modest, consistent diurnal cycles consisting of two daily peaks and two daily troughs observed for all four doses. In addition, the elimination half-life was about 3 hours.
引用
收藏
页码:503 / 509
页数:7
相关论文
共 17 条
[1]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[2]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[3]  
GAINE SP, 1998, AM J RESP CRIT CARE, V157, pA595
[4]   INFECTIOUS COMPLICATIONS AMONG PATIENTS RECEIVING HOME INTRAVENOUS THERAPY WITH PERIPHERAL, CENTRAL, OR PERIPHERALLY PLACED CENTRAL VENOUS CATHETERS [J].
GRAHAM, DR ;
KELDERMANS, MM ;
KLEMM, LW ;
SEMENZA, NJ ;
SHAFER, ML .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 :S95-S100
[5]   Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension [J].
McLaughlin, VV ;
Genthner, DE ;
Panella, MM ;
Rich, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (05) :273-277
[6]   Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series [J].
McLaughlin, VV ;
Genthner, DE ;
Panella, MM ;
Hess, DM ;
Rich, S .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (09) :740-743
[7]   THE PHARMACOKINETICS AND PHARMACODYNAMICS OF THE PROSTACYCLIN ANALOG 15AU81 IN THE ANESTHETIZED BEAGLE DOG [J].
MCNULTY, MJ ;
SAILSTAD, JM ;
STEFFEN, RP .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1993, 48 (02) :159-166
[8]   DIURNAL-VARIATION AND EXERCISE INDUCED CHANGES OF PROSTACYCLIN IN MAN [J].
NADLER, JL ;
YAMAMOTO, JV .
PROSTAGLANDINS LEUKOTRIENES AND MEDICINE, 1986, 22 (01) :71-78
[9]   Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects [J].
Rosenzweig, EB ;
Kerstein, D ;
Barst, RJ .
CIRCULATION, 1999, 99 (14) :1858-1865
[10]   Treatment of pulmonary hypertension secondary to connective tissue diseases [J].
Sanchez, O ;
Humbert, M ;
Sitbon, O ;
Simonneau, G .
THORAX, 1999, 54 (03) :273-277